Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Garre schreef op 29 september 2021 16:36 :
Alles dik groen en we zakken en wederom niks geen nieuws te vinden. Nou ik snap er echt niks meer van,wie wel hier? Niemand denk ik. Heb ook niks van de conferenties gehoord afgelopen maand,iemand daar nog iets van gezien of gehoord?
is een triestig boel mijn slechtste aandeel ooit
Upgrade schreef op 28 september 2021 18:35 :
Gewoon een beetje wachten Garre. net nog bijgekocht!!!!!
Je had ook beter gewacht gaan terug naar de 3,45
Dat zeg je over al uw aandelen : Biocartis, Mithra, Celyad, Galapagos, ... zet die ploat af
Celyad Oncology NASDAQ: CYAD 4,09 USD -0,083 (2,00%)vandaag 29 sep. 14:40 EDT · Disclaimer
www.biospace.com/article/novel-car-t-... Novel CAR T Therapies Help Celyad's CMO Bring Hope to Fearful Patients Published: Sep 29, 2021 By Gail Dutton Charles Morris_Celyad_Company courtesy Celyad Oncology CMO Charles Morris, M.D./Courtesy Celyad Oncology. Immuno-oncology has seen fantastic advances in terms of efficacy and outcomes during the past few years. The challenge, however, is to find ways to identify and add new targets and modalities to bring those advances to even more patients. For Charles Morris, M.D., CMO of Celyad Oncology, that challenge is what makes his work so exciting. “I’ve been in the industry 26 years. After graduating from Sheffield University Medical School in the U.K., I spent six months in a number of rotations, including one in hematological oncology at the Manchester local infirmary," Morris said. “I found, on a personal, emotional level, that you’re dealing with patients who are frightened by their diagnosis, uncertain of their prognosis, and we – the medical staff – were the people who gave them hope. In that way, I found something enjoyable. I liked the work and trying to understand the science of it.” In the 1990s, when he entered oncology, treatment nearly always was confined to chemotherapy. The field had potential – and a dire need – to advance. “Cancer is a difficult nut to crack, and I saw there was potential for things to evolve,” he said. With the combination of bringing value to patients as individuals and as a collective, and the inevitable evolution of the science of oncology, Morris had found his calling. Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies. “Approved cell therapy products have a very, very high response rate,” he said. "The challenge is in expanding that therapy from hematologic malignancies to other targets – in particular, to solid tumors – where we, as a field, haven’t yet cracked the code.” As he elaborated, “all the approved cell therapies are in hematologic malignancies, where the cancer is very accessible to the treatments that are given.” Because the targets that are expressed on myeloma and B cell malignancies aren’t expressed in many other places, the targeting is very specific. Targeting solid tumors, however, is more complex. “Solid tumors are less accessible and have a microenvironment” which complicates the issue. Celyad, therefore, is addressing the challenge from two fronts. Initially, it developed an autologous therapy program for acute leukemia, which is in clinical trials now. “The challenge is that autologous treatment involves a long process,” Morris said. That, effectively delays treatment delivery to patients. Therefore, the company is transitioning to allogeneic CAR T cell therapy, an ‘off-the-shelf’ approach using donor cells rather than the patient’s own cells. “We believe there is a greater opportunity to treat patients with allogeneic therapy,” Morris said. “From the patients’ and physicians’ perspectives, allogeneic therapy is only possible if we minimize the risk of graft versus host disease by knocking down the T cell receptors so they can’t attack normal cells.” From a developer’s perspective, this approach is advantageous, too. There is an almost unlimited supply of cells and the product can be available off-the-shelf or out-of-the-freezer, more like a drug. Because it can be continuously developed, it can be readily available. “A number of companies are pursuing gene editing to develop CAR T therapies, but we have some different techniques,” Morris said, that make Celyad’s approach unique. Specifically, Celyad uses either T cell inhibitory molecules (TIM) or short hairpin RNA (shRNA) to knock down the T cell receptors. “shRNA is our proprietary platform and will do most of the work, although the TIM platform is further advanced.” As CMO, Morris is balancing the concerns of multiple stakeholders. “Physicians, patients, board members, development teams and investors all want effective therapies, and they each have expectations as to how quickly they can be developed and at what costs. Sometimes you have to go slowly to ensure safety. So, balancing expectations is a critical part of what a CMO must do.” One of the strategies Morris uses to do that is to “explain the development process in ways that keep people engaged and excited. A product is great, looking back, when it succeeds, but getting it to that point takes a lot of planning.” Morris counts his first drug approval as the one professional success that will live with him the longest. “The first time you’re part of a team that gets a drug approved, there’s a sense that we developed something that will really help people,” he said. For him, that drug was Faslodex® (fulvestrant), which treats metastatic breast cancer. It was developed while he was with AstraZeneca. “I occasionally meet someone who was treated with it, and I take satisfaction in knowing we are still helping people many years after the interaction with the (regulatory) agencies ceased,” Morris said. Since then, he has been instrumental in the development programs at Radius Health, PsiOxus Therapeutics, ImmunoGen Inc., Allos Therapeutics and Cephalon, Inc. Morris helped Cephalon gain approval for Treanda® (bendamustine), its first oncology drug. His professional success is rooted in truly enjoying his work. To maintain that enjoyment, “continue to find new approaches and new things to do,” he advised. The emphasis on new approaches was one of the key attractants of Celyad. “We have a great team that’s working on the leading edge of science, and we enjoy working together.” There’s more to a successful career, of course. “You also must listen to multiple stakeholders, because it’s not all about the medical role," Morris said. "You have to be confident in your ability to make decisions. If you maintain a patient-centric approach, you can make the right decision, but keeping everything in focus is a balancing act.” As with many companies, that balancing act is multinational. Many of Celyad’s senior executives are based on the U.S. East Coast while “most of the company” is located near Brussels. Morris will make his first trip to meet the Belgian team in person soon. “There’s a value in getting together in the same room, getting to know people socially,” he said. “That’s hard to do through Zoom.” Balance is an integral part of Morris’ life. “Having interests and distractions – walking, running, cycling, listening to music, watching soccer and football – are important. They help make sure people don’t become robots, obsessed with one thing. For me, walking is a little escape. During COVID, I started calling my walks ‘mental health walks’. They give one thinking time.”
Celyad Oncology NASDAQ: CYAD 4,16 USD +0,050 (1,22%)vandaag 30 sep. 16:00 EDT · Disclaimer
Celyad plant presentaties op SITC-jaarcongres Het Waalse biofarmabedrijf Celyad Oncology CYAD3,45% gaat drie korte presentaties (abstracts) geven op het jaarcongres van de Society for Immunotherapy of Cancer (SITC) dat van 10 tot 14 november in Washington D.C. en virtueel plaatsvindt. De posters die daarbij beschikbaar zullen worden gesteld, bevatten bijkomende informatie over Celyads technologie, zijn eerste allogene celtherapiekandidaat CYAD-203 en over het fase 1b-onderzoek met CYAD-101 tegen refractaire metastatische colorectale kanker.
1 min + 7 % en dan ploef naar beneden haha grappig aandeeltje je moet het maar in portefeuille hebben
Hopende schreef op 1 oktober 2021 15:17 :
Celyad plant presentaties op SITC-jaarcongres
Het Waalse biofarmabedrijf Celyad Oncology CYAD3,45%
gaat drie korte presentaties (abstracts) geven op het jaarcongres van de Society for Immunotherapy of Cancer (SITC) dat van 10 tot 14 november in Washington D.C. en virtueel plaatsvindt. De posters die daarbij beschikbaar zullen worden gesteld, bevatten bijkomende informatie over Celyads technologie, zijn eerste allogene celtherapiekandidaat CYAD-203 en over het fase 1b-onderzoek met CYAD-101 tegen refractaire metastatische colorectale kanker.
Één van je betere posts! Bedankt hopende !
Hopende schreef op 1 oktober 2021 16:04 :
1 min + 7 % en dan ploef naar beneden haha grappig aandeeltje je moet het maar in portefeuille hebben
verander je je alias binnenkort zeker in "Kopende"?
[quote alias=egeltjemetstekel id=13715971 date=202110011917] [...] verander je je alias binnenkort zeker in "Kopende"? [/quote0 In Amerika zeker niet blijkbaar
Hopende schreef op 1 oktober 2021 19:30 :
In Amerika zeker niet blijkbaar
Nee maar daar spreken ze een andere taal hè?
Hopende schreef op 1 oktober 2021 15:17 :
Celyad plant presentaties op SITC-jaarcongres
Het Waalse biofarmabedrijf Celyad Oncology CYAD3,45%
gaat drie korte presentaties (abstracts) geven op het jaarcongres van de Society for Immunotherapy of Cancer (SITC) dat van 10 tot 14 november in Washington D.C. en virtueel plaatsvindt. De posters die daarbij beschikbaar zullen worden gesteld, bevatten bijkomende informatie over Celyads technologie, zijn eerste allogene celtherapiekandidaat CYAD-203 en over het fase 1b-onderzoek met CYAD-101 tegen refractaire metastatische colorectale kanker.
Toevallig ben ik zelf hartstikke jarig op 13 november. De grote vraag is wat gaat celyad me dan voor kado geven? Gezien alle door mij genomen investeringsrisicos x mijn aantal celyad aandeeltjes in Porto zou je toch een flinke bom duiten mogen verwachtten. Gaan jullie dan allemaal voor mij zingen? (Graag geen bittere liederen)
laten we hopen dat we uit volle borst kunnen zingen op een zo lang verwachte opsteker :)
Iemand een idee waarom het zo sterk daalt ineens?
Hopende schreef op 4 oktober 2021 16:54 :
[...]
oh zijn het al gewoon geen logische verklaring meer voor open communicatie met de aandeelhouders ja mijn g.t
Veel stuks ook,iemand koopt alles op, dus kan nog wel eens interessant wezen. Vorige week ook zo op 3,89 gestaan. En benieuwd, geen nieuws gevonden nog
Maar niemand die het weet,zoals verwacht, geen pijl meer op te trekken
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee